Commonwealth Diagnostics International (CDI) Named Among the Top Healthcare Technology Companies of 2022

Salem, Mass. – August 11, 2022 – Commonwealth Diagnostics International, Inc. (CDI), an innovative GI health company providing industry-leading diagnostic tests and tools to help physicians identify and diagnose common sources of digestive distress and functional gastrointestinal ailments, is proud to be recognized as one of the Top 100 Healthcare Technology Companies of 2022 by…

Latest Issue of Modern Gastro Now Available

The second issue of Modern Gastro presented by CDI featuring the latest functional gastrointestinal (GI) trends and insights is now available in digital format. Featured articles in the Q3 2022 issue of Modern Gastro include: Mid-Year Update from CDI’s President & CEO Industry Insights from recent GI Community Discussions Highlights from the Mid-Year 2022 Functional…

Inaugural Issue of Modern Gastro Now Available

Commonwealth Diagnostics International Inc. (CDI) is proud to announce that the first release of Modern Gastro is now available in digital format. The magazine, also distributed complimentary in print format to select gastroenterologists nationwide, features functional gastrointestinal (GI) trends and insights. Featured articles in the inaugural issue of Modern Gastro include: Highlights from the 2021…

Commonwealth Diagnostics International, Inc. Cofounders Honored Amongst Peers in Business and Healthcare

Salem, Mass. – June 29, 2021 – Commonwealth Diagnostics International, Inc. (CDI) is pleased to announce that two of its cofounders, Craig Strasnick and Gray W. Rifkin, were honored recently amongst their peers in both business and healthcare. Strasnick, CDI President and CEO, was named to the Forbes Next 1000 list of upstart entrepreneurs redefining…

Commonwealth Diagnostics International, Inc. (CDI) announces expanded industry and research partnerships in the United States and abroad

Salem, Mass. – May 21, 2021 – Over the past 10 years, Commonwealth Diagnostics International, Inc. (CDI) leadership team has worked closely with industry stakeholders to support the gastroenterology (GI) community. Today, CDI is pleased to announce it has expanded partnerships with several industry and research partners both in the United States and abroad, including…

IBSchek® Granted PLA Code from AMA; CDI to Now Accept Insurance, Providing More Patients At-Home Access

Maximum out-of-pocket cost for first clinically validated IBS blood test also to be reduced, making it the most affordable IBS diagnostic test on the market Salem, Mass. – February 3, 2021 – For too long millions of patients requiring a simple and reliable blood test for Irritable Bowel Syndrome (IBS) have been met with soaring…